Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth

robot
摘要生成中

Harrow (HROW) is expected to report a significant year-over-year increase in earnings and revenues for the quarter ended December 2025. Despite this, the company’s Zacks Earnings ESP of -0.42% and Zacks Rank #4 (Sell) suggest it may not beat consensus EPS estimates, making it a less compelling earnings-beat candidate. In contrast, BioCryst Pharmaceuticals (BCRX), also in the same industry, shows a higher probability of beating estimates due to a positive Earnings ESP and Zacks Rank #3 (Hold).

此页面可能包含第三方内容,仅供参考(非陈述/保证),不应被视为 Gate 认可其观点表述,也不得被视为财务或专业建议。详见声明
  • 赞赏
  • 评论
  • 转发
  • 分享
评论
请输入评论内容
请输入评论内容
暂无评论